Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0904 Lumen ECP
BioCentury & Getty Images

Emerging Company Profile

Lumen growing lean, green biologics with $16M series B and Gates funding

Having wrangled spirulina into making oral biologics, Lumen aims for low cost and high volume

Having wrangled spirulina into making oral biologics, Lumen aims for low cost, high volume indications in the Western and developing worlds.

Sep 4, 2020 | 6:28 PM GMT

Having turned photosynthetic bacteria into protein production machines, Lumen believes it has cracked the code to making cheap, oral biologics for widespread diseases in the Western and developing worlds.

The company’s $16 million series

Read the full 969 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE